<DOC>
	<DOCNO>NCT01218217</DOCNO>
	<brief_summary>SQ109 develop aim shorten TB treatment provide new drug resistant TB . The drug demonstrate efficacy toxicology study acceptable safety profile first-in-man study . The objective study evaluate extend early bactericidal activity ( EBA ) , safety , tolerability , pharmacokinetics several dos SQ109 without Rifampicin ( RIF ) 14 day adult newly diagnose , uncomplicated , smear positive , pulmonary TB .</brief_summary>
	<brief_title>Early Bactericidal Activity ( EBA ) SQ109 Adult Subjects With Pulmonary TB</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>1 . Provide sign write informed consent study participation , include HIV testing ( HIV serostatus know last documented negative four week prior enrolment ) . 2 . Be eighteen ( 18 ) 64 ( inclusive ) year age . 3 . Have body weight ( light clothing shoe ) 40 90 kg , inclusive . 4 . Have newly diagnose , previously untreated , uncomplicated , sputum smearpositive , pulmonary TB . 5 . Have chest Xray , opinion Investigator , compatible TB . 6 . Is sputum positive direct microscopy acidfast bacillus ( least 1+ IUATLD/WHO scale ( Appendix 3 ) . 7 . Is able produce adequate spot sputum sample , indicate overnight sputum volume least 10 mL . 8 . Female patient childbearing potential must negative serum pregnancy test , consent practice two effective method birth control abstain sexual intercourse , unless partner ( ) surgically sterile postmenopausal menses last 12 month . Preferably , contraceptive measure continue completion TB treatment , least one month last dose IMP , unless partner ( ) sterile ( , woman bilateral oophorectomy hysterectomy postmenopausal least 12 consecutive month ) . Two follow method may use , one may hormonal : tubal ligation , vaginal diaphragm , intrauterine device , condom , oral contraceptive , contraceptive implant , combine hormonal patch , combine injectable contraceptive depotmedroxyprogesterone acetate , partner ( ) vasectomy . 9 . Male participant must agree use adequate method contraception abstain sexual intercourse throughout participation trial 12 week last dose , unless bilateral orchidectomy . 10 . A Karnofsky score least 60 ( require occasional assistance able care his/her need , see Appendix 5 ) 1 . Poor general condition delay treatment tolerate per discretion Investigator . 2 . Treatment drug active MTB within 3 month prior Visit 1 ( include , limited INH , EMB , RIF , PZA , amikacin , cycloserine , rifabutin , streptomycin , kanamycin , paraaminosalicylic acid , rifapentine , thioacetazone , capreomycin , fluoroquinolone , thioamides , metronidazole ) . 3 . Sputum isolate resistant RIF detect rapid assay native sputum 4 . A history allergy IMP related substance . 5 . Clinically significant evidence extrathoracic TB ( miliary TB , abdominal TB , urogenital TB , osteoarthritic TB , TB meningitis ) , judge investigator . 6 . A history previous TB . 7 . Evidence serious lung condition TB uncontrolled obstructive bronchial disease . 8 . Laboratory parameter do , within 14 day prior , screen : Serum amino aspartate transferase ( AST ) and/or serum alanine aminotransferase ( ALT ) activity &gt; 3 time upper limit normal Serum total bilirubin level &gt; 2.5 time upper limit normal Serum creatinine level &gt; 2 time upper limit normal Complete blood count hemoglobin level &lt; 7.0 g/dL Platelet count &lt; 50,000/mm3 Serum potassium &lt; 3.5 meq/L 9 . History , presence , evidence neuropathy epilepsy . 10 . Clinically relevant change ECG atrioventricular ( AV ) block , prolongation QRS complex 120 millisecond , either QTcF QTcB interval 450 millisecond screen ECG . 11 . A history , current clinically relevant cardiovascular disorder myocardial infarction , heart failure , coronary heart disease , hypertension , arrhythmia , tachyarrhythmia . Family history sudden death unknown cardiacrelated cause , prolong QTc interval . Concomitant use drug know prolong QTc interval ( include amiodarone , bepridil chloroquine , chlorpromazine , cisapride , cisapride , clarithromycin , disopyramide dofetilide , domperidone , droperidol , erythromycin , halofantrine , haloperidol , ibutilide , levomethadyl , lumefantrine , mesoridazine , methadone , pentamidine , pimozide , procainamide , quinidine , sotalol , sparfloxacin , terfenadine , thioridazine ) . 12 . Diabetics use insulin . 13 . Evidence clinically significant metabolic , gastrointestinal , neurological , psychiatric endocrine disease , malignancy , abnormality ( indication study ) . 14 . Any disease condition use standard TB drug component contraindicate , include limited allergy TB drug , component IMPs . 15 . Any disease condition medicinal product list section pertain prohibit medication ( see 4.10.4 ) use . 16 . Known suspected , current history within past 2 year , alcohol drug abuse , , opinion investigator , sufficient compromise safety cooperation patient . Opiates prescribed cough relief count drug abuse . 17 . Prior administration SQ109 . 18 . Is pregnant , breastfeeding , plan conceive father child within one month cessation treatment . 19 . Use drug substance within 30 day prior dose know strong inhibitor inducer cytochrome P450 enzyme ( include xenobiotics , quinidine , tyramine , ketoconazole , testosterone , quinine , gestodene , metyrapone , phenelzine , doxorubicin , troleandomycin , cyclobenzaprine , erythromycin , cocaine , furafylline , cimetidine , dextromethorphan ) . Exceptions may make subject receive 3 day less one drug substance , washout period equivalent least 5 halflives drug substance . 20 . Use therapeutic agent within 30 day prior dose know alter major organ function ( e.g. , barbiturate , opiate , phenothiazine , cimetidine ) . 21 . Use systemic glucocorticoid within three month prior dose . 22 . HIV infection helper/inducer T lymphocyte ( CD4 cell ) count 250 106/L . 23 . Receiving antiretroviral therapy ( ART ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>TB</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>EBA</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Early Bactericidal Activity</keyword>
</DOC>